S2P 주식 개요 심세어 제약 그룹 유한회사는 중국의 유통업체와 약국 체인 및 기타 제약 제조업체를 위한 의약품의 연구, 개발, 제조 및 판매에 종사합니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
Simcere Pharmaceutical Group Limited 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Simcere Pharmaceutical Group 과거 주가 현재 주가 HK$0.81 52주 최고치 HK$0.89 52주 최저치 HK$0.57 베타 0.44 1개월 변경 0% 3개월 변경 사항 10.20% 1년 변경 사항 5.19% 3년 변화 -16.92% 5년 변화 n/a IPO 이후 변화 -44.14%
최근 뉴스 및 업데이트
Simcere Pharmaceutical Group Limited Announces Approval for Marketing of Sanbexin Sublingual Tablets in China by the National Medical Products Administration Dec 02
Simcere Pharmaceutical Group Limited Announces Inclusion of Three Innovative Drugs, Cosela, Enlituo and Sanbexin, in the New National Reimbursement Drug List Nov 28
Simcere Pharmaceuticals Group Ltd. Announces That A New Clinical Study with Major Clinical Findings Regarding Sanbexin (Edaravone and Dexborneol Concentrated Solution for Injection) Has Been Published At the 16th World Stroke Conference Oct 30
First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023) Sep 29
Simcere Pharmaceuticals Group Ltd. Announces Breakthrough Therapy Designation for Sanbexin Sublingual Tablets Granted by the United States Food and Drug Administration Sep 05
First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023) Aug 25 더 많은 업데이트 보기
Simcere Pharmaceutical Group Limited Announces Approval for Marketing of Sanbexin Sublingual Tablets in China by the National Medical Products Administration Dec 02
Simcere Pharmaceutical Group Limited Announces Inclusion of Three Innovative Drugs, Cosela, Enlituo and Sanbexin, in the New National Reimbursement Drug List Nov 28
Simcere Pharmaceuticals Group Ltd. Announces That A New Clinical Study with Major Clinical Findings Regarding Sanbexin (Edaravone and Dexborneol Concentrated Solution for Injection) Has Been Published At the 16th World Stroke Conference Oct 30
First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023) Sep 29
Simcere Pharmaceuticals Group Ltd. Announces Breakthrough Therapy Designation for Sanbexin Sublingual Tablets Granted by the United States Food and Drug Administration Sep 05
First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023) Aug 25
Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by the National Medical Products Administration Aug 22
Simcere Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024 Aug 09
Now 22% overvalued Aug 03
Simcere Pharmaceutical Group Limited Announces New Drug Application of Quviviq (Daridorexant Hydrochloride Tablets) Has Been Accepted by the National Medical Products Administration Jul 17
Simcere Pharmaceutical Group Limited Announces Regular Approval of Xiannuoxin, an Anti-Sars-Cov-2 Innovative Drug Jul 11
Simcere Pharmaceutical Group Limited and Mabpharm Limited Announce Approval on the Marketing of ENLITUO in China by the National Medical Products Administration of China Jun 25 Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback for 260,976,161 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2024. Jun 20
Upcoming dividend of CN¥0.16 per share Jun 11
Simcere Pharmaceutical Group Limited Announces Phase III Clinical Study of Daridorexant Hydrochloride Tablets in the Treatment of Insomia Patients in China Jun 01
Simcere Pharmaceutical Group Limited and Idorsia Pharmaceuticals Ltd. Announces the Hypnotics Daridorexant Hydrochloride Tablets Obtains the Certificate of Drug/ Product Registration Issued by the Pharmacy and Poisons Board of Hong Kong May 23
Full year 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.36 in FY 2022) Apr 26
Dividend of CN¥0.16 announced Mar 22 Simcere Pharmaceutical Group Limited, Annual General Meeting, Jun 14, 2024
Simcere Pharmaceutical Group Limited Announces New Drug Application of Suvemcitug for Injection Accepted by the National Medical Products Administration of China Mar 16
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0500 for Injection (A Humanized Gprc5d-Bcma-Cd3 Trispecific Antibody) Issued by the National Medical Products Administration Mar 13
Simcere Pharmaceutical Group Limited Announces Approval of the Investigational New Drug for SIM0500 Mar 12
Simcere Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024 Mar 09
Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023 Feb 20
Simcere Pharmaceutical Group Limited Announces Publication by New England Journal of Medicine About Phase II/III Clinical Studies Results of XIANNUOXIN for Treatment of Adult Patients with Mild-yo-Moderate COVID-19 Jan 19
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0501 Tablets Jan 12
Simcere Pharmaceutical Group Limited Announces Localization Application of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China Dec 27
Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug for SIM0501 (An Usp1 Small-Molecule Inhibitor) Issued by U.S. Food and Drug Administration Dec 04
Simcere Pharmaceutical Group Limited and Neurodawn Pharmaceutical Co., Ltd. Obtains Clinical Trial Approval Issued by the National Medical Products Administration Nov 30
Simcere Pharmaceutical Group Limited Announces Approval of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China Oct 31
Simcere Pharmaceutical Group Limited Announces the Clinical Trial Approval for New Indication of Sim0237 for Injection (Anti-Pd-L1/IL-15 Bispecific Antibody) Issued by the National Medical Products Administration Oct 17
First half 2023 earnings released: EPS: CN¥0.87 (vs CN¥0.024 in 1H 2022) Sep 25
First half 2023 earnings released: EPS: CN¥0.87 (vs CN¥0.024 in 1H 2022) Aug 22
Simcere Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 21, 2023 Aug 10
Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration Jul 28
Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration Jul 23
Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023. Jul 01 Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023. Jun 30
Co-Founder recently sold €271k worth of stock Jun 21
Simcere Pharmaceutical Group Limited Approves Final Cash Dividend for the Year Ended December 31, 2022, Payable on 12 July 2023 Jun 16
Upcoming dividend of CN¥0.16 per share at 2.3% yield Jun 12
Co-Founder recently sold €360k worth of stock May 01
Full year 2022 earnings released: EPS: CN¥0.36 (vs CN¥0.58 in FY 2021) Apr 19
Investor sentiment improves as stock rises 19% Apr 13
Simcere Pharmaceutical Group Limited Announces Conditional Approval for Marketing in China of Anti-Sars-Cov-2 Innovative Drug Xiannuoxin Tm Granted by the National Medical Products Administration Jan 30
Investor sentiment deteriorated over the past week Jan 20
Simcere Pharmaceutical Group Limited Announces Appointment Wang Xi as an Executive Director and the Appointment of Sung Ka Woon as an Independent Non-Executive Director Jan 19
Now 30% undervalued Jan 18
Simcere Pharmaceutical Group Limited Announces Acceptance of New Drug Application of Anti-SARS-CoV-2 Innovative Drug Xiannuoxin (Simnotrelvir Tablets/Ritonavir Tablets (Co-Packaged)) by the National Medical Products Administration Jan 17
Co-Founder recently bought €957k worth of stock Jan 11 Simcere Pharmaceutical Group Limited Appoints Mr. Tang Renhong as the Chairman of the Board of Directors and Chief Executive Officer of Simcere Zaiming Pharmaceutical Co., Ltd., with Effect from January 1, 2023
Simcere Pharmaceutical Group Limited Announces - the Clinical Trial Approval for SIM0348 Injection (Humanized TIGIT/PVRIG Bispecific Antibody) Issued by the National Medical Products Administration Dec 30
Investor sentiment improved over the past week Dec 30
Simcere Pharmaceutical Group Announces Phase II/III Clinical Trial of Its 3Cl-Targeting anti-SARS-CoV-2 Drug Candidate Complete All Patients Enrollment Dec 21
Simcere Pharmaceutical Group Limited Announces A Phase II/III Clinical Study of Anti-Sars-COV-2 Drug Candidate XIANNUOXIN (SIM0417) Complete All Patients Enrollment Dec 19
Simcere Pharmaceutical Group Limited Announces A Multi-Center, Randomized, Double-Blind, Parallel and Placebo-Controlled Phase III Clinical Study Dec 03
Insufficient new directors Nov 16
Simcere Pharmaceutical Group Limited Announces Executive Changes Nov 10
Investor sentiment improved over the past week Nov 03
Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug Application Oct 28
Investor sentiment improved over the past week Oct 15
Simcere Pharmaceutical Group Limited Appoints Tamas Oravecz as SVP Sep 07
Simcere Pharmaceutical Group Limited Appoints Tamas Oravecz as SVP Sep 06
First half 2022 earnings released: EPS: CN¥0.02 (vs CN¥0.21 in 1H 2021) Sep 01
Simcere Pharmaceutical Group Limited Announces Executive and Committee Changes Sep 01
Simcere Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 31, 2022 Aug 20
Simcere Pharmaceutical Group Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022 Aug 02
Cosela, the World's First Comprehensive Myeloprotection Drug Against Chemotherapy Damage, Wins Approval in China Jul 19
Simcere Pharmaceutical Group Limited Announces Conditional Marketing of COSELA (Trilaciclib Hydrochloride for Injection) in China by the National Medical Products Administration Jul 14
Investor sentiment improved over the past week Jul 09
Simcere Pharmaceutical Group Limited Declares Final Dividend for the Year Ended December 31, 2021, Payable on July 15, 2022 Jun 25
Upcoming dividend of CN¥0.15 per share Jun 21 Simcere Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended December 31, 2021 Jun 02
Simcere Pharmaceutical Group Limited Announces Appointment of Tang Renhong as Co-Chief Executive Officer May 26
Investor sentiment improved over the past week May 18
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0417 (3Cl) Issued by the National Medical Products Administration May 17
CFO & Executive Director recently bought €66k worth of stock Apr 30
Full year 2021 earnings released: EPS: CN¥0.58 (vs CN¥0.28 in FY 2020) Apr 28
Less than half of directors are independent Apr 27
Simcere Pharmaceutical Group Limited Obtains Permission from the National Medical Products Administration of China to Conduct Clinical Trials Apr 01
Investor sentiment improved over the past week Mar 21
Vivoryon Therapeutics N.V. and Simcere Pharmaceutical Group Ltd Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer's Disease Mar 01
Simcere Pharmaceutical Group Announces Primary Endpoint Met in Phase III Clinical Trial of Trilaciclib in Chinese Patients with Small Cell Lung Cancer Feb 24
Simcere Pharmaceutical Group Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2021 Feb 22
Simcere Pharmaceuticals Announces Appointment of Bijoyesh Mookerjee as Chief Medical Officer, Oncology Feb 08
Simcere Pharmaceutical Group Limited Announces the Approval of Investigational New Drug for SIM0235 Issued by U.S. Food and Drug Administration Jan 31
Investor sentiment improved over the past week Jan 18
Center for Drug Evaluation of the National Medical Products Administration of China Includes Simcere Pharmaceutical Group Limited's Trilaciclib Injection as a Priority Review Drug Dec 23 Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0235 Issued by National Medical Products Administration
Simcere Pharmaceutical Group Limited Announces Conditional Approval on the Marketing of Enweida (Envafolimab) in China by The national Medical Products Administration Nov 27
Investor sentiment improved over the past week Nov 19
Co-Founder recently bought €127k worth of stock Nov 02 주주 수익률 S2P DE Pharmaceuticals DE 마켓 7D -2.4% -0.3% -0.3% 1Y 5.2% -17.0% 7.0%
전체 주주 수익률 보기
수익률 대 산업: S2P 지난 1년 동안 -17 %를 반환한 German Pharmaceuticals 산업을 초과했습니다.
수익률 대 시장: S2P 지난 1년 동안 7 %를 반환한 German 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is S2P's price volatile compared to industry and market? S2P volatility S2P Average Weekly Movement 7.0% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
안정적인 주가: S2P 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.
시간에 따른 변동성: S2P 의 주간 변동성 ( 7% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 심세어 제약 그룹은 중국의 유통업체와 약국 체인 및 기타 제약 제조업체를 위한 의약품의 연구, 개발, 제조 및 판매에 종사하고 있습니다. 이 회사는 종양학, 중추신경계, 자가 면역, 항감염, 심혈관 등 다양한 치료 분야에 중점을 두고 있습니다. 주요 제품으로는 에다라본 및 덱스본 농축액 주사제인 산벡신, 재조합 인간 엔도스타틴 주사제인 엔도스타, 엔바폴리맙 주사제인 엔웨이다, 트리라시클립 염산염 주사제인 코셀라, 이구라티모드 정제인 이레모드, 심노트렐비르 정제/리토나비르 정제인 시안누오신 등이 있습니다.
자세히 보기 Simcere Pharmaceutical Group Limited 기본 사항 요약 Simcere Pharmaceutical Group 의 수익과 매출은 시가총액과 어떻게 비교하나요? S2P 기본 통계 시가총액 €2.09b 수익(TTM ) -€145.12m 수익(TTM ) €834.62m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) S2P 손익 계산서(TTM ) 수익 CN¥6.34b 수익 비용 CN¥1.45b 총 이익 CN¥4.88b 기타 비용 CN¥5.99b 수익 -CN¥1.10b
주당 순이익(EPS) -0.44 총 마진 77.05% 순이익 마진 -17.39% 부채/자본 비율 14.5%
S2P 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기 기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2024/12/26 00:45 장 마감 주가 2024/12/23 00:00 수익 2024/06/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Simcere Pharmaceutical Group Limited 16 애널리스트 중 5 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Sharon Shi BOCI Research Ltd. Shaojing Tong BofA Global Research Bo Yu China International Capital Corporation Limited
13 더 많은 분석가 보기 